ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
暂无分享,去创建一个
L. Paz-Ares | J. Zugazagoitia | N. Isambert | A. Martínez-Martí | S. Ponce | M. Jaderberg | C. Ricordel | V. Levitsky | M. Herrera-Juárez | S. Cedres | S. Viteri | Alejandro Navarro | Mathieu Lederlin | Xavier Serres | S. Vetrhus | Thomas Birkballe Hansen
[1] C. Gridelli,et al. Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). , 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] P. Zucali,et al. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress , 2023, Frontiers in Immunology.
[3] J. Wolchok,et al. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] N. Pavlakis,et al. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma , 2022, Lung Cancer.
[5] A. Mansfield,et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Leigh,et al. The Significance of Short Latency in Mesothelioma for Attribution of Causation: Report of a Case with Predisposing Germline Mutations and Review of the Literature , 2021, International Journal of Environmental Research and Public Health.
[7] K. Hemminki,et al. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden , 2021, BMC Cancer.
[8] N. Girard,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] C. Richards,et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial , 2021, The Lancet. Oncology.
[10] D. Fennell,et al. Perspectives on the Treatment of Malignant Pleural Mesothelioma. , 2021, The New England journal of medicine.
[11] M. Péoc'h,et al. The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review , 2021, Cancers.
[12] Sung-il Cho,et al. Future Incidence of Malignant Mesothelioma in South Korea: Updated Projection to 2038 , 2021, International journal of environmental research and public health.
[13] J. Menis,et al. Immunotherapy in malignant pleural mesothelioma: a review of literature data , 2021, Translational lung cancer research.
[14] G. Scagliotti,et al. Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma , 2021, Cancers.
[15] A. Addeo,et al. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma , 2021, Human vaccines & immunotherapeutics.
[16] T. Gambichler,et al. Advances in Targeting Cutaneous Melanoma , 2021, Cancers.
[17] H. Lan,et al. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements , 2021, Cancers.
[18] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[19] G. Zalcman,et al. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment , 2021, Therapeutic advances in medical oncology.
[20] A. Hemminki,et al. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors , 2020, Molecular therapy oncolytics.
[21] K. Hotta,et al. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma , 2020, Journal for ImmunoTherapy of Cancer.
[22] J. Rasko,et al. The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy , 2019, Front. Oncol..
[23] A. Chella,et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. , 2019, The Lancet. Oncology.
[24] P. Hearing,et al. Adenoviral strategies to overcome innate cellular responses to infection , 2019, FEBS letters.
[25] Samuel G. Armato,et al. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1) , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] R. Shavelle,et al. Life Expectancy in Pleural and Peritoneal Mesothelioma , 2017, Lung cancer international.
[27] L. Vassilev,et al. Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model , 2016, International journal of cancer.
[28] Olivier Molinier,et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[29] J. Karbach,et al. Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers , 2016, Journal of Immunotherapy for Cancer.
[30] A. Jegannathen,et al. Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review , 2013, BMJ Case Reports.
[31] G. Fasola,et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience , 2012, BMC Research Notes.
[32] G. Ceresoli,et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. , 2011, Lung cancer.
[33] Maciej S. Lesniak,et al. The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses , 2011, Oncotarget.